The presentation of a pelvic mass poses a diagnostic dilemma for clinicians. While often benign, the potential for malignancy necessitates a thorough evaluation to differentiate benign from malignant masses and guide treatment decisions.
Diagnostic uncertainty can compromise surgical planning, delay timely care, and increase patient anxiety.
undergo surgery for pelvic mass each year
GlcyoKnow Ovarian is a laboratory-developed test (LDT) that aids in the assessment of malignancy risk in confirmed pelvic masses prior to planned surgery.
By analyzing specific biomarkers, GlycoKnow Ovarian provides the likelihood of malignancy that complements imaging findings and clinical judgement, facilitating more informed and personalized treatment decisions.
Clinical Utility of GlycoKnow Ovarian
-Enhanced Diagnostic Accuracy: Provides a more accurate assessment of malignancy risk compared to traditional methods.
-Optimized Surgical Management: Helps determine the optimal surgical approach and the need for referral to a gynecologic oncologist.
-Improved Patient Outcomes: Facilitates timely and shared decision-making, optimizing surgical planning and improving overall patient care.
Streamlining pelvic mass management and optimizing patient care
Single-tube blood draw
87% Sensitivity and 90% Specificity
Rapid 10-day turnaround time
By clicking submit, you confirm that you are a U.S. resident and you agree to receive information about InterVenn, including information about any of its current or future products or product candidates or disease state information, and you acknowledge that you have read and agree to the Terms of Use and Privacy Policy. All personal information will be kept confidential and will not be shared with any parties other than InterVenn, its affiliates and their designated agents.
View our privacy policy.
Proteins undergo a variety of post-translational modifications. Glycosylation, the enzymatic attachment of sugar structures, is one of the most abundant and critical of these modifications, impacting more than 70% of proteins, altering their function and structure2. Protein glycosylation is a critical feature associated with tumor development, including ovarian cancer.
GlycoKnow Ovarian unlocks the glycoproteome using novel high-throughput mass spectrometry technologies paired with AI-powered data processing and machine learning. It measures both the abundance of and the variation in glycosylation profiles of glycoproteins in serum isolated from blood, providing an unprecedented view into the systemic response of the body to the progression of ovarian cancer.
Learn MoreGlycoKnow Ovarian was developed utilizing our proprietary technology platform, GlycoVision. We offer biomarker development services that enable the generation of new disease insights and the discovery of a robust pipeline of biomarkers for early disease detection, response prediction, disease prognosis, and therapeutic monitoring.
1. Bast RC Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer. 2012 May;22 Suppl 1(Suppl 1):S5-8. doi: 10.1097/IGC.0b013e318251c97d. PMID: 22543921; PMCID: PMC3389992..
2. An H.J., Froehlich J.W., Lebrilla C.B. Determination of glycosylation sites and site-specific heterogeneity in glycoproteins. Curr. Opin. Chem. Biol. 2009;13:421–426. doi: 10.1016/j.cbpa.2009.07.022.
InterVenn Biosciences’ clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity clinical laboratory testing, and complies with College of American Pathologists (CAP) Proficiency Testing requirements. The GlycoKnow Ovarian test is developed, and its performance characteristics determined, by InterVenn Biosciences. The GlycoKnow Ovarian test has not been cleared or approved by the U.S. Food and Drug Administration.
2 Tower Place, 5th Floor,
South San Francisco, CA 94080
Bay Area Lab
